Testicular Cancer Research at City of Hope
June 8, 2026
This page was reviewed under our medical and editorial policy by Alexander Chehrazi-Raffle, M.D., assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope®Duarte Cancer Center and Ali Zhumkhawala, M.D., associate professor, Department of Surgery, City of Hope® Duarte Cancer Center.
A Recognized Leader in Testicular Cancer Research
City of Hope is constantly developing new therapies to eradicate your testicular cancer and help you return to an active, healthy life. We conduct a wide variety of clinical trials, many of them not available to the general public. Our latest research covers new state-of-the-art robotic surgical techniques and innovative chemotherapy and other options.
Testicular Cancer Research Projects
City of Hope is a leader in testicular cancer research, with a team dedicated to furthering new treatments and supportive therapies. Our testicular cancer team is available to talk to patients about the treatments available now and those that may still be in the research phase.
Featured Clinical Trials
- Accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: a randomised phase III trial. Open in City of Hope Cancer Center Duarte only
- Phase 1 trial of Pedmark in Men Receiving Cisplatin for Metastatic Germ Cell Tumor. Open in City of Hope Duarte and City of Hope Orange County Lennar Foundation Cancer Center
Publications
- Gismondi CBL, Agarwal R, Teixeira MFB, Chehrazi-Raffle A. Olaparib Response in a Patient With Platinum-Refractory Germ Cell Tumor Harboring a Somatic BRIP1 Mutation. JCO Precis Oncol. 2026 Jan;10:e2500768. doi: 10.1200/PO-25-00768. Epub 2026 Jan 8. PMID: 41505681; PMCID: PMC12799257.
- Hassoun R, Ben-David R, Sfakianos JP, Laliotis G, Au C, Cary C, Masterson TA, Manage K, Dutta P, Tillu N, Cumarasamy S, King J, Rich J, Rock A, Dorff T, Patel M, Sharma S, ElNaggar AC, Liu MC, Tan A, Einhorn LH, Adra N, Chehrazi-Raffle A. Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors. JCO Precis Oncol. 2025 Sep;9:e2500176. doi: 10.1200/PO-25-00176. Epub 2025 Sep 24. Erratum in: JCO Precis Oncol. 2026 Mar;10:e2600181. doi: 10.1200/PO-26-00181. PMID: 40991885.
- Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime-Casas S, Barragan-Carrillo R, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO Open. 2025 May;10(5):105081. doi: 10.1016/j.esmoop.2025.105081. Epub 2025 May 1. PMID: 40315659; PMCID: PMC12098135.
- Chehrazi-Raffle A, Budde LE, Pal SK. Boosting CAR T cells with anti-tumor mRNA vaccines. Nat Med. 2023 Nov;29(11):2711-2712. doi: 10.1038/s41591-023-02623-x. PMID: 37932550.